These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15598951)

  • 1. Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience.
    Tsimberidou AM; Giles FJ; Khouri I; Bueso-Ramos C; Pilat S; Thomas DA; Cortes J; Kurzrock R
    Ann Oncol; 2005 Jan; 16(1):139-45. PubMed ID: 15598951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pilot study of low-dose interleukin-11 in patients with bone marrow failure.
    Kurzrock R; Cortes J; Thomas DA; Jeha S; Pilat S; Talpaz M
    J Clin Oncol; 2001 Nov; 19(21):4165-72. PubMed ID: 11689585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses.
    Wu HH; Talpaz M; Champlin RE; Pilat SR; Kurzrock R
    Cancer; 2003 Dec; 98(11):2410-9. PubMed ID: 14635076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
    Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
    Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombopoietic factors in chronic bone marrow failure states: the platelet problem revisited.
    Kurzrock R
    Clin Cancer Res; 2005 Feb; 11(4):1361-7. PubMed ID: 15746033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I/II study of interleukin-3 in patients with aplastic anemia and myelodysplasia.
    Nimer SD; Paquette RL; Ireland P; Resta D; Young D; Golde DW
    Exp Hematol; 1994 Aug; 22(9):875-80. PubMed ID: 8062886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Phase II clinical trial on China manufactured recombinant human interleukin-11 derivative in the prevention and treatment of chemotherapy-induced thrombocytopenia].
    Wang XY; Feng FY; Song ST; Wang HQ; Zhang MH; Liu J; Liu XY; Xu LG; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2005 Jun; 27(6):373-6. PubMed ID: 16117903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia.
    Gordon MS; Nemunaitis J; Hoffman R; Paquette RL; Rosenfeld C; Manfreda S; Isaacs R; Nimer SD
    Blood; 1995 Jun; 85(11):3066-76. PubMed ID: 7538815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
    Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
    Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
    Oliva EN; Alati C; Santini V; Poloni A; Molteni A; Niscola P; Salvi F; Sanpaolo G; Balleari E; Germing U; Fenaux P; Stamatoullas A; Palumbo GA; Salutari P; Impera S; Avanzini P; Cortelezzi A; Liberati AM; Carluccio P; Buccisano F; Voso MT; Mancini S; Kulasekararaj A; Morabito F; Bocchia M; Cufari P; Spiriti MA; Santacaterina I; D'Errigo MG; Bova I; Zini G; Latagliata R
    Lancet Haematol; 2017 Mar; 4(3):e127-e136. PubMed ID: 28162984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Very low doses of GM-CSF administered alone or with erythropoietin in aplastic anemia.
    Kurzrock R; Talpaz M; Gutterman JU
    Am J Med; 1992 Jul; 93(1):41-8. PubMed ID: 1626572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effectiveness and safety of recombinant human interleukin-11 in the treatment of chemotherapy-induced thrombocytopenia].
    Lei W; Liang J; Chen WG; Ma XZ; Xu M; Du LL
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):542-4. PubMed ID: 17147124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
    Crump M; Couture F; Kovacs M; Saragosa R; McCrae J; Brandwein J; Huebsch L; Beauregard-Zollinger L; Keating A
    Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effectiveness and safety of rhIL-11 in the treatment of chemotherapy-induced thrombocytopenia].
    Li L; Xu CG; Wang XW; Guo QS; Sun YH; Sun LM
    Zhonghua Zhong Liu Za Zhi; 2005 Jun; 27(6):377-9. PubMed ID: 16117904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant and sequential administration of recombinant human granulocyte colony-stimulating factor and recombinant human interleukin-3 to accelerate hematopoietic recovery after autologous bone marrow transplantation for malignant lymphoma.
    Lemoli RM; Rosti G; Visani G; Gherlinzoni F; Miggiano MC; Fortuna A; Zinzani P; Tura S
    J Clin Oncol; 1996 Nov; 14(11):3018-25. PubMed ID: 8918500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome.
    Montero AJ; Estrov Z; Freireich EJ; Khouri IF; Koller CA; Kurzrock R
    Leuk Lymphoma; 2006 Oct; 47(10):2049-54. PubMed ID: 17071475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical study of rhIL-11 for prevention and treatment of chemotherapy-induced thrombocytopenia].
    Sun XF; Guan ZZ; Huang H; Zhou QH; Yi C; Zhang LJ; Zhu J; Li R; Zhou J; Zhang M; Guo Y
    Ai Zheng; 2002 Aug; 21(8):892-5. PubMed ID: 12478901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The efficacy and mechanism of rhIL-11 in the management of chemotherapy-induced thrombocytopenia in acute leukemia].
    Cui XL; Wang L; Gao J; Qin P; Shi Y; Peng J; Hou M
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):345-7. PubMed ID: 16185478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial.
    Lee JW; Lee SE; Jung CW; Park S; Keta H; Park SK; Kim JA; Oh IH; Jang JH
    Lancet Haematol; 2019 Nov; 6(11):e562-e572. PubMed ID: 31474546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.